Royer Biomedical, Inc. Receives FDA Approval to Proceed With Human Testing (IND 111446) on 5/25/2012 for its AppliGel Polymer Drug Delivery System

Published: Jun 01, 2012

FREDERICK, Md.--(BUSINESS WIRE)--Royer Biomedical, Inc. (RBI) received FDA approval to proceed with Human Testing of AppliGel-G (Gentamicin) in management of Diabetic Foot Ulcers (DFU). AppliGel is a patented proprietary dissolvable non-immunogenic Polymer Drug Delivery System Platform. It has demonstrated efficacy in biofilm and infection eradication, without significant systemic API levels.

Back to news